---
title: "BMRN: Amicus integration, VOXZOGO growth, and pipeline expansion fuel rare disease leadership"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295673076.md"
description: "Rare disease focus and global scale drive strong revenue growth and improved profitability. Amicus acquisition accelerates de-leveraging and adds high-growth assets, while VOXZOGO and pipeline expansion support future growth.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T13:33:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295673076.md)
  - [en](https://longbridge.com/en/news/295673076.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295673076.md)
generator: "portal-rs"
---

# BMRN: Amicus integration, VOXZOGO growth, and pipeline expansion fuel rare disease leadership

Rare disease focus and global scale drive strong revenue growth and improved profitability. Amicus acquisition accelerates de-leveraging and adds high-growth assets, while VOXZOGO and pipeline expansion support future growth.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)
- [FOLD.US](https://longbridge.com/en/quote/FOLD.US.md)

## Related News & Research

- [BioMarin EVP, Chief Legal Officer Sold Shares Worth Over $1.1M](https://longbridge.com/en/news/297967016.md)
- [BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics](https://longbridge.com/en/news/297679488.md)
- [BioMarin Chief Legal Officer George Eric Davis disposes of 17,557 shares worth $1.16 million](https://longbridge.com/en/news/297964982.md)
- [CASI Pharmaceuticals sells Alesta stake to BioMarin for US$5.9 million](https://longbridge.com/en/news/297773958.md)
- [EVP At BioMarin Pharmaceutical Sells $1.16M Of Stock](https://longbridge.com/en/news/298054481.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**